Long-term study of ML-007C-MA in adults with schizophrenia
Tests ML-007C-MA over one year in adults with schizophrenia.
Plain-language title generated from the registry record
Registry title: A Long-Term Open-Label Study of ML-007C-MA in Adults With Schizophrenia
Key facts
- Where
- Ann Arbor, Atlanta, Austin, Bellflower, Boston, Cedarhurst, Cerritos, Chicago, Culver City, Decatur, DeSoto, Flowood, Gaithersburg, Garden Grove, Hollywood, Houston, Las Vegas, Lemon Grove, Little Rock, Long Beach, Los Angeles, Marlton, Miami, Miami Lakes, Montclair, New York, North Canton, Oceanside, Orange, Philadelphia, Pico Rivera, Richardson, Riverside, Rogers, San Diego, Sherman Oaks, Staten Island, The Bronx, Torrance, Watertown, West Chester, and West Palm Beach, United StatesSee the 42 sites
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07459647, who can take part
Where in United States
- Ann ArborAnn Arbor, United StatesTaking people
- AtlantaAtlanta, United StatesTaking people
- AustinAustin, United StatesTaking people
- BellflowerBellflower, United StatesTaking people
- BostonBoston, United StatesTaking people
- CedarhurstCedarhurst, United StatesTaking people
- CerritosCerritos, United StatesTaking people
- ChicagoChicago, United StatesTaking people
- Culver CityCulver City, United StatesTaking people
- DecaturDecatur, United StatesTaking people
- DeSotoDeSoto, United StatesTaking people
- FlowoodFlowood, United StatesTaking people
- GaithersburgGaithersburg, United StatesTaking people
- Garden GroveGarden Grove, United StatesTaking people
- HollywoodHollywood, United StatesTaking people
- HoustonHouston, United StatesTaking people
- Las VegasLas Vegas, United StatesTaking people
- Lemon GroveLemon Grove, United StatesTaking people
- Little RockLittle Rock, United StatesTaking people
- Long BeachLong Beach, United StatesTaking people
- Los AngelesLos Angeles, United StatesTaking people
- MarltonMarlton, United StatesTaking people
- MiamiMiami, United StatesTaking people
- Miami LakesMiami Lakes, United StatesTaking people
- MontclairMontclair, United StatesTaking people
- New YorkNew York, United StatesTaking people
- North CantonNorth Canton, United StatesTaking people
- OceansideOceanside, United StatesTaking people
- OrangeOrange, United StatesTaking people
- PhiladelphiaPhiladelphia, United StatesTaking people
- Pico RiveraPico Rivera, United StatesTaking people
- RichardsonRichardson, United StatesTaking people
- RiversideRiverside, United StatesTaking people
- RogersRogers, United StatesTaking people
- San DiegoSan Diego, United StatesTaking people
- Sherman OaksSherman Oaks, United StatesTaking people
- Staten IslandStaten Island, United StatesTaking people
- The BronxThe Bronx, United StatesTaking people
- TorranceTorrance, United StatesTaking people
- WatertownWatertown, United StatesTaking people
- West ChesterWest Chester, United StatesTaking people
- West Palm BeachWest Palm Beach, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- MapLight Therapeutics
- Trial code
- NCT07459647
- Record updated
- 15 October 2026
- Original description
ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study (ML-007C-MA-211) or enroll directly (De Novo Cohort).Read full original descriptionShow less
An Open-Label Study to Assess the Long-Term Safety, Tolerability, and Effectiveness of ML-007C-MA in Adult Participants With Schizophrenia
ML-007C-MA-212 is a 52-week open-label study designed to evaluate the long-term safety, tolerability, and effectiveness of ML-007C-MA in participants with schizophrenia who have recently completed an antecedent study (ML-007C-MA-211) or enroll directly (De Novo Cohort).
Inclusion: Must be able and willing to provide informed consent for all required study procedures; Has a primary diagnosis of schizophrenia based on the DSM-5 criteria that is confirmed by semi-structured clinical interview (Mini International Neuropsychiatric Interview for DSM-5); May benefit from long-term pharmacotherapy for schizophrenia, based on assessment of the investigator; Is appropriate for an outpatient level of care and resides in a stable living situation, based on assessment of the investigator; Has an identified reliable informant(s) available to participate in relevant assessments. Site staff may serve as the informant if the site has had regular contact with the participant for >1 year.
Exclusion: Has any DSM-5 disorder, other than schizophrenia, within the 12 months before Screening that is primarily responsible for the current symptoms or functional impairment; Is discontinuing effective and well-tolerated antipsychotic therapy for the purpose of enrolling in this study; Has received any prohibited therapy within the Screening Period unless discontinued before Baseline; Has a DSM-5 diagnosis of moderate to severe substance use disorder (except tobacco or caffeine use disorder) within the 12 months before Screening (confirmed using MINI version 7.0.2 at Screening); Has a known allergy to ML-007C-MA, its active ingredients or their excipients; Has clinically significant abnormal physical examination, ECG, or clinical safety laboratory result at Screening or Baseline; Has current evidence of a clinically significant and/or unstable medical comorbidity at Screening or Baseline; Has an elevated risk of suicidal behavior; Has an elevated risk of violent or destructive behavior, based on participant history and investigator judgment.